

**Xadago (safinamide)
Inbrija (levodopa)
Effective 10/1/19**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Parkinson disease symptoms are due to lack of striatal dopamine. Levodopa circulates in the plasma to the blood-brain-barrier (BBB), where it crosses, to be converted by striatal enzymes to dopamine. Inbrija is an oral inhalation of levodopa.

Xadago (safinamide) is a monoamine oxidase inhibitor type-B (MAOI-B) indicated for the adjunctive treatment of patients with Parkinson’s Disease (PD) who are experiencing “off” episodes.

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Xadago or Inbrija excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members with Parkinson disease experiencing “off” episodes when all the following criteria are met, and documentation is provided:

1. Member is concurrently taking carbidopa/levodopa.
2. Member is ≥ 18 years of age
3. Member is experiencing “off” symptoms with carbidopa/levodopa therapy
4. Member has had an inadequate response or adverse reaction to selegiline **AND** rasagiline
5. **For Inbrija only**, the member has an inadequate response or adverse reaction to selegiline, rasagiline **AND** Xadago

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member’s condition.



Limitations

- 1. Initial approvals will be for 6 months.
- 2. Reauthorizations will be for 12 months
- 3. The following quantity limits apply:

Inbrija 42mg	300 capsules per 30 days
--------------	--------------------------

References

- 1. Xadago (safinamide) [prescribing information]. Louisville, KY: US WorldMeds; June 2017
- 2. Selegiline Hydrochloride Capsules [prescribing information]. Weston, FL: Apotex Corp; June 2014
- 3. Azilect (rasagiline) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA; December 2018
- 4. Inbrija (levodopa) [prescribing information]. Ardsley, NY: Acorda Therapeutics; December 2018
- 5. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. *J Pharmacol Exp Ther.* 1975;195(3):453-464.[PubMed 489]

Review History

09/24/18 – Reviewed
06/19/19 – Added Inbrija
09/18/19 – Reviewed

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.